In these settings, B-cell activation appears an early event in NASH [35,37], as the onset of experimental NASH is accompanied by a significant expansion of the fraction of CD43−/CD23+ B2-cells that contribute to hepatic inflammation by producing pro-inflammatory cytokines such as TNF-α and IL-6. The gene discussed is SPN; the disease is metabolic dysfunction-associated steatohepatitis.